Effective treatment of inflammatory disease models with exosomes derived from dendritic cells genetically modified to express IL-4

Journal of Immunology

Volumn 179, Issue 4, 2007, Pages 2242-2249

  Seon, Hee Kim ^a   Bianco, Nicole R ^a   Shufesky, William J ^a   Morelli, Adrian E ^a   Robbins, Paul D ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; COLLAGEN; FAS ANTIGEN; FAS LIGAND; GLYCOPROTEIN P 15095; INTERLEUKIN 4; CD1 ANTIGEN; HLA ANTIGEN CLASS 2;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; BONE MARROW CELL; CELL MIGRATION; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DISEASE SEVERITY; DNA MODIFICATION; DRUG EFFICACY; EXOSOME; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; INCIDENCE; INFLAMMATORY DISEASE; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; TREATMENT OUTCOME; ANIMAL; AUTOIMMUNE DISEASE; DBA MOUSE; DERMIS; GENE EXPRESSION; GENETIC TRANSDUCTION; GENETICS; IMMUNOLOGY; INFLAMMATION; SPLEEN; T LYMPHOCYTE;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, CD1; ANTIGENS, CD3; ARTHRITIS, EXPERIMENTAL; AUTOIMMUNE DISEASES; BONE MARROW CELLS; DENDRITIC CELLS; DERMIS; GENE EXPRESSION; HISTOCOMPATIBILITY ANTIGENS CLASS II; HYPERSENSITIVITY, DELAYED; INFLAMMATION; INTERLEUKIN-4; MICE; MICE, INBRED DBA; SPLEEN; T-LYMPHOCYTES; TRANSDUCTION, GENETIC;

EID: 34848915428     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.4.2242     Document Type: Article

References (33)

1. Essner, R., K. Rhoades, W. H. McBride, D. L. Morton, and J. S. Economou. 1989. IL-4 down-regulates IL-1 and TNF gene expression in human monocytes. J. Immunol. 142: 3857-3861.
2. 2. Proc. Natl. Acad. Sci. USA 86: 3803-3807.
3. Joosten, L. A., E. Lubberts, M. M. Helsen, T. Saxne, C. J. Coenen-de Roo, D. Heinegard, and W. B. van den Berg. 1999. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis. Arthritis Res. 1: 81-91.
4. Kim, S. H., C. H. Evans, S. Kim, T. Oligino, S. C. Ghivizzani, and P. D. Robbins. 2000. Gene therapy for established murine collagen-induced arthritis by local and systemic adenovirus-mediated delivery of interleukin-4. Arthritis Res. 2: 293-302.
5. Kang, I., W. W. Lee, and Y. Lee. 2000. Modulation of collagen-induced arthritis by IL-4 and dexamethasone: the synergistic effect of IL-4 and dexamethasone on the resolution of CIA. Immunopharmacology 49: 317-324.
6. Myers, L. K., B. Tang, J. M. Stuart, and A. H. Kang. 2002. The role of IL-4 in regulation of murine collagen-induced arthritis. Clin. Immunol. 102: 185-191.
7. Santiago-Schwarz, F. 1999. Positive and negative regulation of the myeloid dendritic cell lineage. J. Leukocyte Biol. 66: 209-216.
8. + peripheral blood dendritic cells are differentially regulated by cytokines. J. Immunol. 163: 3250-3259.
9. +) dendritic cells: association with conversion from liver transplant tolerance to acute rejection. Transplantation 69: 2647-2657.
10. Penna, G., M. Vulcano, A. Roncari, F. Facchetti, S. Sozzani, and L. Adorini. 2002. Differential chemokine production by myeloid and plasmacytoid dendritic cells. J. Immunol. 169: 6673-6676.
11. Asselin-Paturel, C., G. Brizard, K. Chemin, A. Boonstra, A. O'Garra, A. Vicari, and G. Trinchieri. 2005. Type I interferon dependence of plasmacytoid dendritic cell activation and migration. J. Exp. Med. 201: 1157-1167.
12. Morita, Y., J. Yang, R. Gupta, K. Shimizu, E. A. Shelden, J. Endres, J. J. Mule, K. T. McDonagh, and D. A. Fox. 2001. Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis. J. Clin. Invest. 107: 1275-1284.
13. Kim, S. H., S. Kim, C. H. Evans, S. C. Ghivizzani, T. Oligino, and P. D. Robbins. 2001. Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4. J. Immunol. 166: 3499-3505.
14. Guery, L., G. Chiocchia, F. Batteux, M. C. Boissier, and C. Fournier. 2001. Collagen II-pulsed antigen-presenting cells genetically modified to secrete IL-4 down-regulate collagen-induced arthritis. Gene Ther. 8:1855-1862.
15. Kim, S. H., S. Kim, T. J. Oligino, and P. D. Robbins. 2002. Effective treatment of established mouse collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express FasL. Mol. Ther. 6: 584-590.
16. Zhang, H. G., P. Yang, J. Xie, Z. Liu, D. Liu, L. Xiu, T. Zhou, Y. Wang, H. C. Hsu, and J. D. Mountz. 2002. Depletion of collagen II-reactive T cells and blocking of B cell activation prevents collagen II-induced arthritis in DBA/1j mice. J. Immunol. 168: 4164-4172.
17. Zhang, H. G., M. Fleck, E. R. Kern, D. Liu, Y. Wang, H. C. Hsu, P. Yang, Z. Wang, D. T. Curiel, T. Zhou, and J. D. Mountz. 2000. Antigen presenting cells expressing Fas ligand down-modulate chronic inflammatory disease in Fas ligand-deficient mice. J. Clin. Invest. 105: 813-821.
18. Zhang, H. G., D. Liu, Y. Heike, P. Yang, Z. Wang, X. Wang, D. T. Curiel, T. Zhou, and J. D. Mountz. 1998. Induction of specific T-cell tolerance by adenovirus-transfected, Fas ligand-producing antigen presenting cells. Nat. Biotechnol. 16: 1045-1049.
19. Min, W. P., R. Gorczynski, X. Y. Huang, M. Kushida, P. Kim, M. Obataki, J. Lei, R. M. Suri, and M. S. Cattral. 2000. Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival. J. Immunol. 164: 161-167.
20. Zitvogel, L., A. Regnault, A. Lozier, J. Wolfers, C. Flament, D. Tenza, P. Ricciardi-Castagnoli, G. Raposo, and S. Amigorena. 1998. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat. Med. 4: 594-600.
21. Aline, F., D. Bout, S. Amigorena, P. Roingeard, and I. Dimier-Poisson. 2004. Toxoplasma gondii antigen-pulsed-dendritic cell-derived exosomes induce a protective immune response against T. gondii infection. Infect. Immun. 72: 4127-4137.
22. Morelli, A. E., A. T. Larregina, W. J. Shufesky, M. L. Sullivan, D. B. Stolz, G. D. Papworth, A. F. Zahorchak, A. J. Logar, Z. Wang, S. C. Watkins, et al. 2004. Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells. Blood 104: 3257-3266.
23. Segura, E., C. Nicco, B. Lombard, P. Veron, G. Raposo, F. Batteux, S. Amigorena, and C. Thery. 2005. ICAM-1 on exosomes from mature dendritic cells is critical for efficient naive T-cell priming. Blood 106: 216-223.
24. Veron, P., E. Segura, G. Sugano, S. Amigorena, and C. Thery. 2005. Accumulation of MFG-E8/lactadherin on exosomes from immature dendritic cells. Blood Cells Mol. Dis. 35: 81-88.
25. Kim, S. H., E. R. Lechman, N. Bianco, R. Menon, A. Keravala, J. Nash, Z. Mi, S. C. Watkins, A. Gambotto, and P. D. Robbins. 2005. Exosomes derived from IL-10-treated dendritic cells can suppress inflammation and collagen-induced arthritis. J. Immunol. 174: 6440-6448.
26. Kim, S. H., N. Bianco, R. Menon, E. R. Lechman, W. J. Shufesky, A. E. Morelli, and P. D. Robbins. 2006. Exosomes derived from genetically modified DC expressing FasL are anti-inflammatory and immunosuppressive. Mol. Ther. 13: 289-300.
27. Escudier, B., T. Dorval, N. Chaput, F. Andre, M. P. Caby, S. Novault, C. Flament, C. Leboulaire, C. Borg, S. Amigorena, et al. 2005. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of the first Phase I clinical trial. J. Transl. Med. 3: 10.
28. Morse, M. A., J. Garst, T. Osada, S. Khan, A. Hobeika, T. M. Clay, N. Valente, R. Shreeniwas, M. A. Sutton, et al. 2005. A Phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J. Transl. Med. 3: 9-16.
29. Karlsson, M., S. Lundin, U. Dahlgren, H. Kahu, I. Pettersson, and E. Telemo. 2001. "Tolerosomes" are produced by intestinal epithelial cells. Eur. J. Immunol. 31: 2892-2899.
30. Peche, H., M. Heslan, C. Usal, S. Amigorena, and M. C. Cuturi. 2003. Presentation of donor major histocompatibility complex antigens by bone marrow dendritic cell-derived exosomes modulates allograft rejection. Transplantation 76: 1503-1510.
31. Taylor, D. D., and C. Gercel-Taylor. 2005. Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects. Br. J. Cancer 92: 305-311.
32. + T-cell apoptosis. Blood Cells Mol. Dis. 35: 169-173.
33. Frangsmyr, L., V. Baranov, O. Nagaeva, U. Stendahl, L. Kjellberg, and L. Mincheva-Nilsson. 2005. Cytoplasmic microvesicular form of Fas ligand in human early placenta: switching the tissue immune privilege hypothesis from cellular to vesicular level. Mol. Hum. Reprod. 11: 35-41.